Evidence map›Paper›PMID 39345457›Full record

ArticlebioRxiv : the preprint server for biology2024

Merkel cell carcinoma-derived macrophage migration inhibitory factor (MIF) may promote persistence of Chronic Lymphocytic Leukemia.

Gabriel F Alencar, Haroldo J Rodriguez, Thomas H Pulliam, Allison J Remington, Macy W Gilmour, Rian Alam, Austin J Jabbour, Logan J Mullen, Blair L DeBuysscher, Paul Nghiem and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gabriel F AlencarBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Haroldo J RodriguezBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Thomas H PulliamDepartment of Dermatology, University of Washington, Seattle, WA, USA.
Allison J RemingtonDepartment of Dermatology, University of Washington, Seattle, WA, USA.
Macy W GilmourDepartment of Dermatology, University of Washington, Seattle, WA, USA.
Rian AlamDepartment of Dermatology, University of Washington, Seattle, WA, USA.
Austin J JabbourDepartment of Dermatology, University of Washington, Seattle, WA, USA.
Logan J MullenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Blair L DeBuysscherVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Paul NghiemDepartment of Dermatology, University of Washington, Seattle, WA, USA.
Justin J TaylorBeirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0001-9718-2901

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Understand & overcome resistance to PD-1P01CA225517 · NCI · UNIVERSITY OF WASHINGTON · PI Cecilia C Yeung · 2019 to 2026
$22.7M
NCI NIH HHS P01 CA225517NCI NIH HHS P30 CA044579
6 · The paper itself

Abstract

While concurrent diagnoses of Merkel cell carcinoma (MCC) and other cancers, like Chronic lymphocytic leukemia (CLL), are rare, patients with MCC have a 30-fold higher incidence of CLL. While these increases have been attributed to the ability of CLL to suppress immune responses allowing for the emergence of MCC, here we found evidence that MCC could support the persistence of CLL. Using single cell sequencing approaches and computational analyses of MCC and CLL from a patient where both cancers were present in the same lymph node, we found that production of macrophage migration inhibitory factor (MIF) by MCC could promote the persistence of CLL through stimulation of CD74 and CXCR4. These results may explain why blood cell counts rapidly normalized after treatment for MCC and were maintained at normal levels despite the absence of treatment for CLL.

Identifiers

PMID39345457
PMCPMC11429610

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.